SG Americas Securities Invests $5.19M in Dyne Therapeutics

Institutional investor takes stake in biotech firm focused on rare muscle diseases

Apr. 2, 2026 at 9:03am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC, a major financial services firm, has purchased 265,384 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage biotech company developing gene regulation therapies for rare muscular disorders. The $5.19 million investment represents approximately 0.19% ownership in Dyne Therapeutics.

Why it matters

Dyne Therapeutics is a promising biotech startup working on innovative treatments for serious rare diseases like Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy. This investment from a prominent institutional investor like SG Americas Securities signals growing confidence in Dyne's pipeline and technology platform.

The details

SG Americas Securities purchased the 265,384 shares of Dyne Therapeutics in the fourth quarter of 2025, according to a recent SEC filing. The firm's $5.19 million stake makes it one of Dyne's larger institutional investors. Dyne Therapeutics is developing a proprietary gene regulation platform called FORCE to enable targeted delivery of oligonucleotide and gene therapies to skeletal and respiratory muscles.

  • SG Americas Securities bought the Dyne Therapeutics shares in the fourth quarter of 2025.
  • Dyne Therapeutics is a clinical-stage company founded in 2019.

The players

SG Americas Securities LLC

A major financial services firm that has invested $5.19 million to acquire a 0.19% stake in Dyne Therapeutics.

Dyne Therapeutics, Inc.

A clinical-stage biotech company developing gene regulation therapies for rare muscular disorders like Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy.

Got photos? Submit your photos here. ›

The takeaway

This investment from a prominent institutional investor like SG Americas Securities is a vote of confidence in Dyne Therapeutics' innovative approach to treating rare and debilitating muscle diseases. As Dyne continues advancing its pipeline, this capital injection will help fuel its research and development efforts.